Innoviva (INVA) Other Non-Current Liabilities (2014 - 2026)

Innoviva's (INVA) quarterly Other Non-Current Liabilities came in at $69.1 million in Q1 2026, up 485.92% YoY from $11.8 million in Q1 2025, and up 21.21% on a QoQ basis from $57.0 million in Q4 2025.

Innoviva (INVA) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends

Innoviva (INVA) has 13 years of Other Non-Current Liabilities data on file, last reported at $69.1 million in Q1 2026.

  • Quarterly Other Non-Current Liabilities rose 485.92% year-over-year to $69.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.1 million (up 485.92% YoY) and the FY2025 annual result came in at $57.0 million, down 11.3% from the prior year.
  • Other Non-Current Liabilities improved to $69.1 million in Q1 2026, from $57.0 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $78.4 million in Q3 2022 to a low of $1.1 million in Q3 2024.
  • A 5-year average of $58.8 million and a median of $68.6 million in 2023 frame the typical range for Other Non-Current Liabilities.
  • Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 560050.0% — and 2024, when it slumped 98.43%.
  • Tracing INVA's Other Non-Current Liabilities over 5 years: stood at $67.9 million in 2022, then advanced by 5.77% to $71.9 million in 2023, then slipped by 10.57% to $64.3 million in 2024, then retreated by 11.3% to $57.0 million in 2025, then rose by 21.21% to $69.1 million in 2026.
  • The last three Other Non-Current Liabilities figures came in at $69.1 million (Q1 2026), $57.0 million (Q4 2025), and $55.9 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Innoviva 1.54 Bn 968.79 Mn 90.62 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 67.28 Mn
Mar 31, 2026 69.10 Mn
Dec 31, 2025 57.01 Mn
Sep 30, 2025 55.88 Mn
Jun 30, 2025 55.15 Mn
Mar 31, 2025 11.79 Mn
Dec 31, 2024 64.28 Mn
Sep 30, 2024 1.08 Mn
Jun 30, 2024 72.07 Mn
Mar 31, 2024 70.06 Mn
Dec 31, 2023 71.87 Mn
Sep 30, 2023 68.69 Mn
Jun 30, 2023 68.58 Mn
Mar 31, 2023 70.13 Mn
Dec 31, 2022 67.95 Mn
Sep 30, 2022 78.42 Mn
Sep 30, 2021 14,000.00
Jun 30, 2021 45,000.00
Mar 31, 2021 77,000.00
Dec 31, 2020 106,000.00